Related Experiment Videos

Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant

J V Gannon1, R Greaves, R Iggo

  • 1Molecular Immunochemistry Laboratory, Imperial Cancer Research Fund, Potters Bar, Herts, UK.

The EMBO Journal
|May 1, 1990
PubMed

Insights

Point mutations in the p53 gene are common in human cancers, converting p53 into a dominant oncogene. A new antibody, PAb240, specifically detects these mutant p53 forms, aiding cancer diagnosis.

Area of Science:

  • Molecular Biology
  • Oncology
  • Genetics

Background:

  • Point mutations in the p53 gene are frequent in human cancers.
  • Mutant p53 acts as a dominant oncogene, promoting cell immortalization and transformation.

Purpose of the Study:

  • To develop a diagnostic tool for mutant p53.
  • To investigate the conformational changes associated with p53 mutations.

Main Methods:

  • Development of a monoclonal antibody, PAb240, specific for mutant p53.
  • Immunoprecipitation and immunoblotting assays using PAb240 and PAb246 antibodies.
  • Analysis of p53 binding to SV40 large T antigen and HSP70.

Main Results:

  • PAb240 specifically immunoprecipitates mutant p53, not wild-type p53.
  • Mutant p53 recognized by PAb240 shows altered binding properties, including reduced T antigen binding and increased HSP70 binding.
  • PAb240 detects all denatured forms of p53, reacting with mammalian and chicken p53.

Conclusions:

  • Immunoprecipitation with PAb240 is a diagnostic marker for p53 mutations in human and murine systems.
  • p53 mutations induce a common conformational change, abolishing T antigen binding and promoting self-oligomerization.
  • Mutant p53 may function via a dominant-negative mechanism, neutralizing wild-type p53 activity.

Related Concept Videos